1. Home
  2. BMEA vs SUNS Comparison

BMEA vs SUNS Comparison

Compare BMEA & SUNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.27

Market Cap

91.1M

Sector

Health Care

ML Signal

HOLD

Logo Sunrise Realty Trust Inc.

SUNS

Sunrise Realty Trust Inc.

HOLD

Current Price

$7.75

Market Cap

108.7M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMEA
SUNS
Founded
2017
2023
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
91.1M
108.7M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BMEA
SUNS
Price
$1.27
$7.75
Analyst Decision
Strong Buy
Hold
Analyst Count
6
1
Target Price
$9.83
$8.75
AVG Volume (30 Days)
566.6K
53.5K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
16.17%
EPS Growth
69.19
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$70.81
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.84
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$7.34
52 Week High
$2.99
$11.78

Technical Indicators

Market Signals
Indicator
BMEA
SUNS
Relative Strength Index (RSI) 47.54 44.47
Support Level $1.21 $7.79
Resistance Level $1.44 $8.18
Average True Range (ATR) 0.06 0.26
MACD -0.00 -0.02
Stochastic Oscillator 58.14 34.18

Price Performance

Historical Comparison
BMEA
SUNS

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

About SUNS Sunrise Realty Trust Inc.

Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS, and debt-like preferred equity securities across CRE asset classes and investment mix to include high-quality multi-family, condominiums, retail, office, hospitality, industrial, mixed-use, and specialty-use real estate. The company's portfolio is concentrated in the Southern U.S.

Share on Social Networks: